Skip to content

Trial Summary

This study is testing olaparib, in Homologous recombination (HR) deficient metastatic breast and relapsed ovarian cancer in patients who do not have hereditary mutations in BReast CAncer susceptibility gene 1 and gene 2 (BRCA1 and BRCA2).

Acronym:

EMBRACE

ACTRN/NCT /ethics:

ACTRN12617000855325

Scientific title:

A clinical research study testing olaparib, in Homologous recombination (HR) deficient metastatic breast and relapsed ovarian cancer in patients who do not have hereditary mutations in BReast CAncer susceptibility gene 1 and gene 2 (BRCA1 and BRCA2)

Sponsor / Cooperative group:

ANZGOG

Trial & Patient Characteristics

Cancer TypeBreast; Gynaecological
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexFemale
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2017-11-30
Anticipated End Date2020-10-31

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorDr Sid Selva
Recruitment StatusRecruiting